Jonathan Dordick, a chemical and biological engineer at Rensselaer Polytechnic Institute, and an international team of collaborators, developed a platform that can help identify which therapy combinations will most benefit a patient. Read more . . .
Immunotherapies in pancreatic and breast cancers—two prominent and lethal cancer types—are not a home run on their own. These therapies often benefit from working in combination with other treatments, such as antibodies or drugs.